新冠疫情期间的炎症性肠病
Inflammatory bowel diseases during the COVID-19 pandemic.
作者信息
Derda Edyta, Szymańska Edyta, Sokolek Magda, Kierkuś Jarosław
机构信息
Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, The Children's Memorial Health Institute, Warsaw, Poland.
出版信息
Prz Gastroenterol. 2024;19(3):231-235. doi: 10.5114/pg.2024.143143. Epub 2024 Sep 18.
Abstract
Since the beginning of the COVID-19 pandemic in 2020, the safety of those with compromised immune systems and chronic disease has been of particular concern for health care providers. Inflammatory bowel diseases (IBD) are chronic, incurable conditions of digestive system with unknown aetiology, but one of the causes is disordered immune response. Medical therapies most frequently used in IBD are immune suppressing or modifying with the rising use of biologic treatment. All these aspects make patients with Crohn's disease and ulcerative colitis a group of particular risk. Therefore, the aim of this review is to discuss potential mechanisms, risks, and management of patients with IBD during COVID-19 pandemic.
摘要
自2020年新冠疫情开始以来，免疫系统受损者和慢性病患者的安全一直是医疗服务提供者特别关注的问题。炎症性肠病（IBD）是消化系统的慢性、不治之症，病因不明，但其中一个原因是免疫反应紊乱。IBD最常用的药物治疗是免疫抑制或免疫调节，生物治疗的使用也在增加。所有这些因素使克罗恩病和溃疡性结肠炎患者成为一个特别危险的群体。因此，本综述的目的是讨论新冠疫情期间IBD患者的潜在机制、风险和管理。
相似文献
1
Inflammatory bowel diseases during the COVID-19 pandemic.新冠疫情期间的炎症性肠病
Prz Gastroenterol. 2024;19(3):231-235. doi: 10.5114/pg.2024.143143. Epub 2024 Sep 18.
2
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.2018年炎症性肠病对加拿大的影响：直接成本与医疗服务利用情况
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
3
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.《2018年炎症性肠病在加拿大的影响：患有炎症性肠病的儿童和青少年》
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2.
4
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study.维多珠单抗用于儿童炎症性肠病的维持治疗（VEDOKIDS）：一项多中心、前瞻性队列研究的54周结果
Lancet Gastroenterol Hepatol. 2025 Mar;10(3):234-247. doi: 10.1016/S2468-1253(24)00319-4. Epub 2025 Jan 6.
5
The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.2018年加拿大炎症性肠病的影响：炎症性肠病的肠外疾病
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S73-S80. doi: 10.1093/jcag/gwy053. Epub 2018 Nov 2.
6
AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review.AGA 临床实践更新：炎症性肠病患者的饮食和营养治疗：专家综述。
Gastroenterology. 2024 Mar;166(3):521-532. doi: 10.1053/j.gastro.2023.11.303. Epub 2024 Jan 23.
7
Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.炎症性肠病患者感染 SARS-CoV-2 及对 COVID-19 疫苗免疫应答的风险：当前证据。
Front Immunol. 2022 Jun 23;13:933774. doi: 10.3389/fimmu.2022.933774. eCollection 2022.
8
Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Children and Expectant Mothers With Inflammatory Bowel Disease.加拿大克罗恩病与结肠炎协会：2021年加拿大新冠疫情对炎症性肠病的影响——炎症性肠病患儿与准妈妈群体
J Can Assoc Gastroenterol. 2021 Nov 5;4(Suppl 2):S27-S33. doi: 10.1093/jcag/gwab030. eCollection 2021 Dec.
9
Inflammatory Bowel Disease: Clinical Diagnosis and Pharmaceutical Management.炎症性肠病：临床诊断与药物治疗
Med Res Arch. 2023 Jan;11(1). doi: 10.18103/mra.v11i1.3135. Epub 2023 Jan 31.
10
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.通过RAND方法评估炎症性肠病中免疫抑制药物的适用性：意大利炎症性肠病研究小组（IG-IBD）立场声明
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
本文引用的文献
1
Motivational Interviewing as a Strategy to Improve Adherence in IBD Treatment: An Integrative Review Amidst COVID-19 Disruptions.动机性访谈作为改善炎症性肠病治疗依从性的策略：在新冠疫情干扰下的综合综述
Healthcare (Basel). 2024 Jun 18;12(12):1210. doi: 10.3390/healthcare12121210.
2
Mild SARS-CoV-2 infection in vulnerable patients: implementation of a clinical pathway for early treatment.轻症 SARS-CoV-2 感染的脆弱患者：早期治疗临床路径的实施。
Enferm Infecc Microbiol Clin (Engl Ed). 2024 Apr;42(4):195-201. doi: 10.1016/j.eimce.2023.03.003. Epub 2023 Mar 30.
3
Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic.炎症性肠病生物治疗的疾病监测：2019冠状病毒病大流行的早期影响及未来启示
Frontline Gastroenterol. 2020 Sep 30;12(4):345-347. doi: 10.1136/flgastro-2020-101563. eCollection 2021.
4
Changes in the Occurrence of Gastrointestinal Infections after COVID-19 in Korea.韩国新冠肺炎疫情后胃肠道感染发生率的变化
J Korean Med Sci. 2021 Jun 21;36(24):e180. doi: 10.3346/jkms.2021.36.e180.
5
Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden.炎症性肠病与 COVID-19 重症风险：瑞典全国基于人群的队列研究。
United European Gastroenterol J. 2021 Mar;9(2):177-192. doi: 10.1002/ueg2.12049. Epub 2021 Mar 11.
6
Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry.由于 COVID-19，SECURE-IBD 注册研究中的医师在开具炎症性肠病药物方面的实践模式。
J Crohns Colitis. 2021 May 4;15(5):860-863. doi: 10.1093/ecco-jcc/jjaa243.
7
Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce.炎症性肠病在 COVID-19 爆发期间的管理：来自 ECCO-COVID 工作组的十大注意事项。
J Crohns Colitis. 2020 Oct 21;14(14 Suppl 3):S798-S806. doi: 10.1093/ecco-jcc/jjaa160.
8
Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab.儿童克罗恩病和儿童多系统炎症综合征（MIS-C）与 COVID-19 采用英夫利昔单抗治疗。
J Pediatr Gastroenterol Nutr. 2020 Aug;71(2):153-155. doi: 10.1097/MPG.0000000000002809.
9
Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition.2019 年冠状病毒病与小儿炎症性肠病：欧洲小儿胃肠病学、肝病学和营养学学会小儿炎症性肠病波尔图小组的全球经验和临时指南（2020 年 3 月）。
J Pediatr Gastroenterol Nutr. 2020 Jun;70(6):727-733. doi: 10.1097/MPG.0000000000002729.
10
COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020).新型冠状病毒肺炎与炎症性肠病：大流行初期（2020年2月至4月）患者护理及随访中出现的问题
Gastroenterol Hepatol. 2020 Aug-Sep;43(7):408-413. doi: 10.1016/j.gastrohep.2020.05.003. Epub 2020 May 15.
Zotero 插件